Treatment of mild to moderate Graves' ophthalmopathy with sodium diclofenac: a pilot study

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorBLOISE, Walter
dc.contributor.authorMIMURA, Lidia Yuri
dc.contributor.authorMOURA, Janete
dc.contributor.authorNICOLAU, Wilian
dc.date.accessioned2017-11-27T16:23:33Z
dc.date.available2017-11-27T16:23:33Z
dc.date.issued2011
dc.description.abstractObjective: To report the use of sodium diclofenac, an antagonist of PPAR-gamma and cyclooxigenase-2 (COX-2) inhibitor in the treatment of mild to moderate Graves' ophthalmopathy. Subjects and methods: Thirteen patients with clinical activity score (CAS) 2 to 7 were treated during a period ranging from 3 to 12 months (mean 7.8 +/- 3.4) with oral sodium diclofenac, 50 mg every 12 hours. Results: Extra-ocular muscle restriction and CAS improved significantly, p = 0.003 and = 0.004, respectively. Ocular pain and diplopia disappeared, except for one patient who reported improvement of these symptoms. No recurrence was found after interruption of treatment. Conclusions: Treatment of moderate Graves' ophthalmopathy with oral sodium diclofenac is a good, safe and less expensive therapeutic option. Like others new treatment trials, findings must be confirmed in a greater number of patients in a controlled study. Arq Bras Endocrinol Metab. 2011;55(9):692-5
dc.description.abstractOBJETIVO: Relatar o uso do diclofenato de sódio, um antagonista do PPAR-gama e inibidor da ciclooxigenase-2 (COX-2) no tratamento da leve a moderada oftalmopatia de Graves. SUJEITOS E MÉTODOS: Treze pacientes com CAS (clinical activity score) 2 a 7 foram tratados durante um período de 3 a 12 meses (média 7,6 ± 3,4) com diclofenaco de sódio por via oral na dose de 50 mg a cada 12 horas. RESULTADOS: A restrição da musculatura extraocular e o índice CAS melhoraram de modo significativo, respectivamente p = 0,003 e p = 0,004. A dor ocular e a diplopia desapareceram, com exceção de um paciente que referiu melhora desses sintomas. Não houve recidiva após a interrupção do tratamento. CONCLUSÕES: O tratamento da oftalmopatia de Graves de média gravidade com diclofenaco de sódio por via oral é uma opção boa, segura e de baixo custo. Como outros novos tratamentos, ele deverá ser confirmado em um maior número de pacientes em estudos controlados.
dc.description.indexPubMed
dc.identifier.citationARQUIVOS BRASILEIROS DE ENDOCRINOLOGIA E METABOLOGIA, v.55, n.9, p.692-695, 2011
dc.identifier.issn0004-2730
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/22623
dc.language.isoeng
dc.publisherSBEM-SOC BRASIL ENDOCRINOLOGIA & METABOLOGIA
dc.relation.ispartofArquivos Brasileiros de Endocrinologia e Metabologia
dc.rightsopenAccess
dc.rights.holderCopyright SBEM-SOC BRASIL ENDOCRINOLOGIA & METABOLOGIA
dc.subjectModerate Graves' ophtalmopathy
dc.subjecttreatment
dc.subjectsodium diclofenac
dc.subjectPPAR-gamma
dc.subjectcyclooxigenase-2
dc.subjectOftalmopatia de Graves moderada
dc.subjecttratamento
dc.subjectdiclofenaco de sódio
dc.subjectPPAR-gama
dc.subjectciclooxigenase-2
dc.subject.otheractivated receptor-gamma
dc.subject.otherdisease
dc.subject.otherexpression
dc.subject.othertissues
dc.subject.wosEndocrinology & Metabolism
dc.titleTreatment of mild to moderate Graves' ophthalmopathy with sodium diclofenac: a pilot study
dc.title.alternativeTratamento da oftalmopatia de Graves leve a moderada com diclofenato de sódio: um estudo piloto
dc.typearticle
dc.type.categoryoriginal article
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.author.externalMOURA, Janete:Univ Sao Paulo, Fac Med, Hosp Clin, Graves Ophthalmopathy Sect,Thyroid Unit, Sao Paulo, Brazil
hcfmusp.citation.scopus7
hcfmusp.contributor.author-fmusphcWALTER BLOISE
hcfmusp.contributor.author-fmusphcLIDIA YURI MIMURA
hcfmusp.contributor.author-fmusphcWILIAN NICOLAU
hcfmusp.description.beginpage692
hcfmusp.description.endpage695
hcfmusp.description.issue9
hcfmusp.description.volume55
hcfmusp.origemWOS
hcfmusp.origem.pubmed22231971
hcfmusp.origem.scopus2-s2.0-84855839860
hcfmusp.origem.wosWOS:000298988200004
hcfmusp.publisher.cityRIO DE JANEIRO, RJ
hcfmusp.publisher.countryBRAZIL
hcfmusp.relation.referenceAMEMIYA T, 1982, KLIN MONATSBL AUGENH, V181, P286, DOI 10.1055/s-2008-1055220
hcfmusp.relation.referenceGan TJ, 2010, CURR MED RES OPIN, V26, P1715, DOI 10.1185/03007995.2010.486301
hcfmusp.relation.referenceParidaens D, 2005, EYE, V19, P1286, DOI 10.1038/sj.eye.6701768
hcfmusp.relation.referenceFORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0
hcfmusp.relation.referenceAdamson DJA, 2002, MOL PHARMACOL, V61, P7, DOI 10.1124/mol.61.1.7
hcfmusp.relation.referenceMimura LY, 2003, THYROID, V13, P845, DOI 10.1089/105072503322401032
hcfmusp.relation.referenceStarkey K, 2003, J CLIN ENDOCR METAB, V88, P55, DOI 10.1210/jc.2002-020987
hcfmusp.relation.referenceVondrichova T, 2007, THYROID, V17, P511, DOI 10.1089/thy.2007.0028
hcfmusp.relation.referenceBartalena L, 2008, THYROID, V18, P333, DOI 10.1089/thy.2007.0315
hcfmusp.relation.referenceBahn RS, 2010, NEW ENGL J MED, V362, P726, DOI 10.1056/NEJMra0905750
hcfmusp.relation.referenceBanga JP, 2008, THYROID, V18, P973, DOI 10.1089/thy.2007.0406
hcfmusp.relation.referenceBARTALENA L, 2007, PEDIAT ENDOCRINOL S, V2, P210
hcfmusp.relation.referenceDurrani O M, 2005, Orbit, V24, P117, DOI 10.1080/01676830590912562
hcfmusp.relation.referenceEl Fassi D, 2006, THYROID, V16, P709
hcfmusp.relation.referenceKonuk EBY, 2006, EUR J ENDOCRINOL, V155, P681, DOI 10.1530/eje.1.02280
hcfmusp.relation.referenceLee Seongmu, 2007, BMC Ophthalmol, V7, P8, DOI 10.1186/1471-2415-7-8
hcfmusp.relation.referenceSalvi M, 2007, EUR J ENDOCRINOL, V156, P33, DOI 10.1530/eje.1.02325
hcfmusp.relation.referenceSIMSEK J, 2007, AM RHEUM DIS, V66, P255
hcfmusp.scopus.lastupdate2024-04-12
relation.isAuthorOfPublication6cfd4cfb-ed53-46f9-b43b-4bf6014285aa
relation.isAuthorOfPublicationa8ac3503-dc60-44e8-bcc5-1fc69b2c74bb
relation.isAuthorOfPublicationf51504f7-9f30-4802-a2a2-3c7dda85a3b8
relation.isAuthorOfPublication.latestForDiscovery6cfd4cfb-ed53-46f9-b43b-4bf6014285aa
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
art_BLOISE_Treatment_of_mild_to_moderate_Graves_ophthalmopathy_with_2011.PDF
Tamanho:
1.51 MB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/ICHC